In thirty-two NSCLC patients at stages III-IV, the percentage of CD4+Foxp3+ Treg cells in PBMCs was significantly higher than that in patients at stages I-II (2.01 ± 0.23% versus 0.98 ± 0.25%, P < 0.05, Figure 3(a)). Here, FOXP3 is linked to non-small cell lung carcinoma.